Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PAFRY and 80,000+ other tickers.
See exactly how PAFRY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PAFRY and 80,000+ other tickers.
Pan African Resources PLC, headquartered in Johannesburg, South Africa, is primarily engaged in the comprehensive process of gold mining, production, and sale within the country. Its key operations feature the Barberton gold project, which includes three subterranean mines—Fairview, Sheba, and New Consort—situated in the Barberton Greenstone Belt. Another vital asset is the Elikhulu tailings retreatment plant, located in Southern Africa. The company itself was founded in 2000.
RBC Capital Markets has started its coverage of Pan African Resources PLC (LSE:PAF, OTCQX:PAFRY, JSE:PAN) with an Outperform rating and a 155p price target...
RBC Capital Markets has started its coverage of Pan African Resources PLC (LSE:PAF, OTCQX:PAFRY, JSE:PAN) with an Outperform rating and a 155p price target that implies upside of 55%. The broker expects production to rise about 30% to 350,000 ounces annually by FY30, led by Tennant Creek in Australia, which it sees reaching around 100,000 ounces.
Take-Two Interactive Software Inc (NASDAQ:TTWO) reported first-quarter revenue of $1.53 billion, topping analyst estimates of $1.41 billion, as the video...
Palantir Technologies Inc (NYSE:PLTR) shares jumped 20% to about $152 in early trade on Tuesday the company reported second quarter 2026 results that...
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO), arguing that the market's reaction to a failed heart drug trial looks somewhat overdone while...